Medacta Reports on Device Utilization

Results from a 421-patient study revealed a 97.75% survival rate at 5 years for Medacta's AMIStem hip implant, suggesting that the device is a safe and reliable solution for cementless total hip arthroplasty (THA).

AMIStem system is often used with Medacta’s Anterior Minimally Invasive Surgery (AMIS) approach to THA. To date, AMIStem has been...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0